EU drug agency concludes that AstraZeneca benefits outweigh the risks

Home

News

Adam Button

18/03/2021 | 16:07 GMT

But agency says it cannot definitively rule out a like to blood clots

Remains important to keep track of all side effects
Will continue to study possible links to blood clots

This is not the definitive kind of 'this is safe' ruling we'd all like.

ADVERTISEMENT - CONTINUE READING BELOW

Best in 2026

Sponsored

General Risk Warning

Best Prop Firm in 2026: Detailed Comparison

Best Futures Brokers in USA for 2026: Detailed Comparison

Best Prediction Market Platforms in 2026: Detailed Comparison

Best Forex Brokers in 2026: Detailed Comparison

Best Online Brokers in 2026: Detailed Comparison

ADVERTISEMENT - CONTINUE READING BELOW

Telegram Community

Gain Access

RKLB soared 28.5% on upgrades & backlog, but its 70 P/S ratio signals high risk for future returns.

Motley Fool

3m ago

STRA's 11.6% FCF margin limits growth. AAL's 7x EV/EBITDA & weak returns raise red flags.

StockStory

7m ago

AMD's 200%+ run faces AI inference/agentic AI boost. High P/E, but low PEG suggests value.

Motley Fool

14m ago

CLX, SITE, BEN face slow growth & shaky demand. CLX at 14.3x P/E, SITE at 26.7x, BEN at 10.4x.

StockStory

22m ago

Entry-level hiring down 25-50% amid AI fears, but new grad roles up 5.6%. Intern demand improving.

YahooFinance

25m ago

BAX beats revenue/EPS estimates! Sales up 2.9%, EPS 15.9% higher. Turnaround strategy shows promise.

StockStory

29m ago

Spirit Airlines grounded! Investors face 0% returns as low-fare model falters. A cautionary tale.

AP News

32m ago

Telegram Community

Gain Access

Must Read

!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|} !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}